Olink
The test, which is currently available in Hong Kong, uses Olink's technology to measure 21 plasma proteins to aid in the diagnosis of Alzheimer's.
The company was successful in identifying protein panels that can detect the presence of one of 18 types of solid tumor, at early stages, from a blood sample.
Roughly a year after its launch, the company's Multiple Sclerosis Disease Activity (MSDA) test is being used by several dozen clinics around the country.
The assay is designed for a standard microtiter plate format and to be read out using plate readers commonly available in hospitals and other clinical labs.
Olink Proteomics Expanding Biomarker Offerings, Exploring Development of Proprietary Markers
Premium
Some six months after establishing itself as an independent entity, the company plans to roughly double its protein biomarker libraries by the end of the year.